World

World's longest expressway tunnel opens to traffic in Xinjiang, China

Dec 27, 2025

Beijing [China], December 27: The 22.13-km Tianshan Shengli Tunnel, the world's longest expressway tunnel, officially opened to traffic, Xinhua News Agency reported.
Traversing the central Tianshan Mountains in northwest China's Xinjiang Uygur Autonomous Region, the tunnel slashes what was once a several-hour mountain drive to just 20 minutes.
As a vital artery linking city clusters in northern and southern Xinjiang, the G0711 Urumqi-Yuli Expressway, including the tunnel, entered operation on the same day.
Via existing expressways, the new route extends to the Beijing-Tianjin-Hebei region, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area, and the Chengdu-Chongqing region, thereby becoming a key hub that connects China's eastern economic circle with countries in Eurasia.
The expressway, constructed over five years, spans 324.7 kilometers with a total investment of 46.7 billion yuan (about US$6.63 billion).
Stretching 2,500 kilometers, the Tianshan Mountains span central Xinjiang, separating Urumqi, the largest city in the north, from Korla, the largest city in the south.
With the opening of the expressway, travel time between these two major cities is reduced from 7 hours to approximately 3 hours, promoting economic integration between northern and southern Xinjiang and creating new channels for external exchanges.
Source: Emirates News Agency

More news

Sirolimus-Coated Balloon Matches Drug-Eluting Stent at One Year in Large International TRANSFORM II Trial

Tampa (Florida) [US], November 2: Sirolimus-coated balloon (SCB) strategy was non-inferior to contemporary everolimus-eluting stents (EES) for Target Lesion Failure (TLF) at 12 months in patients with de novo coronary artery disease. These are the results of the TRANSFORM II randomised trial, presented today as a Late-Breaking Clinical Trial at TCT 2026 and accepted in The Lancet which confirm how MagicTouch Sirolimus Coated Balloon (Concept Medical) matches contemporary best in class stent. Late-breaking results presented at TCT 2026 show an implant-free strategy with MagicTouch Sirolimus Coated Balloon is non-inferior to everolimus-eluting in de novo coronary artery disease.

Nov 02, 2026